Glimepiride Dispersible Tablets

The active ingredient of this product is glimepiride, which is an oral sulfonylurea hypoglycemic drug. It is used to treat non-insulin-dependent diabetes mellitus. Glimepiride mainly works by stimulating pancreatic β cells to release insulin. Like other sulfonylurea drugs, the effect of glimepiride on pancreatic β cells to release insulin is mainly based on increasing the responsiveness of pancreatic β cells to physiological concentrations of glucose. In addition, glimepiride also has obvious effects outside the pancreas, which also exist in other sulfonylurea drugs. Insulin release: Sulfonylurea drugs regulate insulin secretion by closing the ATP-dependent potassium channels of pancreatic β cell membranes. Closing potassium channels induces β cell membrane depolarization, while opening calcium channels leads to increased calcium ion influx into cells, stimulating insulin release through exocytosis. Glimepiride binds to β cell membrane proteins associated with ATP-dependent potassium channels at a high exchange rate, and its binding site is different from the binding site of traditional sulfonylurea drugs. Extrapancreatic activity: Extrapancreatic effects improve the sensitivity of peripheral tissues to insulin and reduce the uptake of insulin by the liver. Peripheral muscle and adipose tissue take up glucose from the blood through specific transporters located in the cell membrane. The transfer of glucose in these tissues limits the rate of glucose utilization. Glimepiride rapidly increases the number of active glucose transfer molecules in the plasma membrane of muscle and adipocytes, thereby stimulating glucose uptake. Glimepiride increases the activity of glycosyl-phosphatidylinositol-specific phosphatidic acid C, which is related to the drug-induced synthesis of fat and glycogen in isolated fat and muscle cells. Glimepiride inhibits the production of glucose in the liver by increasing the intracellular concentration of fructose 2,6-bisphosphate, thereby inhibiting the formation of glycogen. General pharmacodynamics: The minimum effective oral dose in healthy individuals is about 0.6 mg. The effect of glimepiride is dose-dependent and reproducible. The physiological response of reduced insulin secretion during intense exercise still exists when taking glimepiride. There is no significant difference in the therapeutic effect whether it is administered 30 minutes before meals or immediately before meals. Once-daily administration can well control the metabolism of diabetic patients for 24 hours. Although the hydroxy metabolite of glimepiride causes a small but statistically significant decrease in serum glucose in healthy subjects, this is only a small part of the overall effect of the drug. Combination therapy with insulin: There is limited data on combination therapy with insulin. When patients still cannot effectively control blood sugar with the maximum dose of glimepiride, combined insulin therapy can be started. Two studies have confirmed that combination therapy can achieve the same metabolic control as insulin alone; however, the average dose of insulin required is lower with combination therapy.

Molecular weight: C24H34N4O5S

This product is white tablets.

It is suitable for type 2 diabetes mellitus in which diet, exercise therapy and weight loss cannot adequately control blood sugar.

Take the medication orally as directed by your doctor. For patients with diabetes, there is no fixed dose for glimepiride or any other glucose-lowering drug. Fasting blood glucose and glycated hemoglobin must be measured regularly to determine the minimum effective dose of the patient's medication; glycated hemoglobin levels must be measured to monitor the patient's treatment effect. Usual starting dose: In the initial treatment stage, the starting dose of glimepiride is 1-2 mg once a day, administered at breakfast or the first main meal. Those patients who are sensitive to glucose-lowering drugs should start with 1 mg once a day, and the dose should be adjusted with caution. There is no precise dosage relationship between glimepiride and other oral glucose-lowering drugs. The maximum initial dose of glimepiride does not exceed 2 mg. Usual maintenance dose: The usual maintenance dose is 1-4 mg once a day, and the recommended maximum maintenance dose is 6 mg once a day. The dose reaches

1. Hypoglycemia: This product can cause hypoglycemia, especially in the elderly and weak patients at the beginning of treatment, those who eat irregularly, drink alcohol, and those with liver and kidney damage. According to reports, the incidence rate is 2%. 2. Digestive system symptoms: Nausea and vomiting, diarrhea, and abdominal pain are rare. 3. There are individual cases reported that serum liver transaminases are elevated. 4. Skin allergic reactions: itching, erythema, and urticaria are rare. 5. Others: Headache, fatigue, and dizziness are rare.

People who are allergic to this product are prohibited from using it, and those with allergic constitutions should use it with caution.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

The active ingredient of this product is glimepiride, which is an oral sulfonylurea hypoglycemic drug. It is used to treat non-insulin-dependent diabetes mellitus. Glimepiride mainly works by stimulating pancreatic beta cells to release insulin. Like other sulfonylurea drugs, the effect of glimepiride in stimulating pancreatic beta cells to release insulin is mainly based on increasing the responsiveness of pancreatic beta cells to physiological concentrations of glucose. In addition, glimepiride also has obvious effects outside the pancreas, and this effect also exists in other sulfonylurea drugs. Insulin release: Sulfonylurea drugs regulate insulin secretion by closing the ATP-dependent potassium channels of the pancreatic beta cell membrane. Closing potassium channels induces depolarization of the beta cell membrane, while opening calcium channels leads to an increase in the influx of calcium ions into the cell, stimulating insulin release through exocytosis. Glimepiride exchanges insulin with A at a high exchange rate.

Keep sealed.

2 mg

24 months

CSPC OUYI Pharmaceutical Co., Ltd.

• Founded in:

  2001-03-29

• Address:

  No. 88, Yangzi Road, Shijiazhuang Economic and Technological Development Zone

• Tax NO.:

  91130100601289268L

• Registered Funds:

  298 million yuan

• Website:

  Log in to view

• Email:

  Log in to view